Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6)

Garassino, MC; Mazieres, J; Reck, M; Delmonte, A; Bischoff, HG; Bernabe, R; Perez, ID; Sawyer, W; Trunova, N; Faivre-Finn, C

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (4): S737